Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Short Interest Up 327.4% in July

Posted by on Aug 13th, 2026

Neuphoria Therapeutics Inc. (NASDAQ:NEUP – Get Free Report) was the target of a significant growth in short interest in July. As of July 31st, there was short interest totaling 65,538 shares, a growth of 327.4% from the July 15th total of 15,334 shares. Currently, 1.2% of the shares of the stock are short sold. Based on an average daily volume of 638,720 shares, the short-interest ratio is presently 0.1 days.

Neuphoria Therapeutics Stock Up 0.5%

NEUP stock traded up $0.02 during midday trading on Thursday, hitting $3.83. The company’s stock had a trading volume of 8,922 shares, compared to its average volume of 107,409. The stock’s 50-day moving average price is $3.95 and its 200 day moving average price is $4.37. The stock has a market cap of $20.68 million, a price-to-earnings ratio of -0.35 and a beta of 0.75. Neuphoria Therapeutics has a 1 year low of $3.19 and a 1 year high of $21.40.

Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.47. As a group, equities analysts forecast that Neuphoria Therapeutics will post -4.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Neuphoria Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Merck & Co. Inc. acquired a new stake in shares of Neuphoria Therapeutics in the 2nd quarter valued at $43,818,000. Commonwealth Equity Services LLC acquired a new stake in Neuphoria Therapeutics during the fourth quarter worth about $43,000. XTX Topco Ltd purchased a new position in Neuphoria Therapeutics in the 4th quarter valued at about $47,000. Persistent Asset Partners Ltd grew its position in shares of Neuphoria Therapeutics by 173.1% in the 4th quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock worth $52,000 after acquiring an additional 8,495 shares in the last quarter. Finally, Boothbay Fund Management LLC acquired a new position in Neuphoria Therapeutics during the 4th quarter valued at about $54,000. Institutional investors and hedge funds own 15.90% of the company’s stock.

Wall Street Analysts Forecast Growth

NEUP has been the subject of a number of recent analyst reports. HC Wainwright downgraded shares of Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 15th. Wall Street Zen raised shares of Neuphoria Therapeutics to a “hold” rating in a research report on Saturday, July 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Monday, June 1st. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Neuphoria Therapeutics presently has an average rating of “Hold” and a consensus price target of $21.00.

Get Our Latest Research Report on Neuphoria Therapeutics

Neuphoria Therapeutics Company Profile

(Get Free Report)

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Featured Articles

Receive News & Ratings for Neuphoria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.